Experimental Drug Touted as Breakthrough for Intractable Brain Cancer

Israeli researcher Eilam Yeini examines a microscope image of a blood vessel tube surrounded by cancer tissues, as part of a brain cancer research that uses patients' cells to make 3D printed models of tumors, at Tel Aviv University, Israel, on Aug. 17, 2021. Nir Elias/Reuters

A new experimental drug therapy has shown some promising signs of slowing down the progression of a type of brain cancer by more than 16 months on average.

French drug developer Servier Laboratories released results of a new medication that may become one of the earliest targeted therapies for a type of brain tumor affecting adults under the age of 50.